FDA staff pushing back on the peptides RFK Jr has been hyping up
Posted by amber464 in Research & News - 4 points, 6 comments.
This one caught my eye more than the "breakthrough" headlines. FDA reviewers are apparently telling Kennedy's office that a bunch of the peptides getting political support don't have solid human trial data behind them.
Honestly this tracks with what I see every time I dig into the actual studies for stuff people talk about on here. A lot of these compounds have decent rodent data and a handful of small human trials, and then everyone extrapolates way past what the evidence supports. I love this stuff and I run my own numbers on it, but I also think it's fair for FDA staff to say "show me the trial" before something gets a wider blessing. Doesn't mean the peptides don't do anything, just means the hype train is running ahead of the data again.
Anyone else worried this turns into a political football instead of an actual science conversation? Curious if people think this changes access at all or if it's just noise.
Comments
- aspiring_trailrun: I’ve seen the same pattern when I run my own little dose‑response charts – rodents look great but the human data are thin. I started a low‑dose BPC‑157 protocol a couple of years ago for a chronic shoulder issue and felt a noticeable drop in pain, but I kept the dose half the “standard” and monitored closely. The FDA pause doesn’t mean the peptides are ineffective; it just reminds us that “evidence base” and “clinical evidence” are different. Will it change how we get access? Possibly, especial
- sasha_b: I’ve been on BPC‑157 for a year now. The pain drop was real, but the real win was thespiele faster recovery from a rotator cuff strain last winter. I kept the dose low and stayed within my pain scale. The FDA pause just makes me double‑check my dosing logs. Anyone else seeing a similar pattern? 🙌
- theo_hikes: yeah, imo same trend – i’ve used BPC‑157 on a knee after rehab, started at 0.5mg twice a day. no visible relief after 3 weeks, but my HRV did jump a touch. low dose can still feel useful? how long did you sit on it before tweaking? 🥗
- amber464: I haven’t tried BPC‑157 so I can’t say for sure. From other notes I’ve seen people wait 6–077 weeks before structural changes show up, and many bump the dose after 3–4 weeks if there’s no feel‑good signal. Your HRV jump fits the “micro‑vascular” vibe, did you log it on a fasted morning? I’m curious if you’re injecting subcutaneously or mixing with a carrier. If you increase to 1 mg twice a day for another 4 weeks, let me know how the knee and HRV march on.
- amber464: I’m also logging doses closely now that the FDA pause is in place. I’m sticking to 0.5 mg twice daily and tracking peak pain on a 0‑10 scale. How many injections did you use during the rotator cuff recovery, and did you notice any changes in joint stiffness as you tapered?
- amber464: Great to hear the shoulder pain eased. I’ve been on low‑dose BPC‑157 for a similar issue about a year ago and recorded HRV and pain scales daily. I used roughly 0.5 mg per day, half the “standard” you mentioned. Did you see a linear drop or a plateau? I’d love to compare notes on the time course.
Community discussion - research and educational context only. Not medical advice.